Pioglitazone for the primary and secondary prevention of cardiovascular and renal outcomes in patients with or at high risk of type 2 diabetes mellitus: a meta-analysis

Quantifying heterogeneity in a meta‐analysis

Higgins, J. P. T., & Thompson, S. G. (2002) · Statistics in Medicine · doi:10.1002/sim.1186 · Cited by 36,763 · see citing works

The Cochrane Collaboration's tool for assessing risk of bias in randomised trials

Higgins, J. P. T., Altman, D. G., Gotzsche, P. C., Juni, P., Moher, D., Oxman, A. D., Savovic, J., Schulz, K. F., Weeks, L., Sterne, J. A. C., et al. (2011) · BMJ · doi:10.1136/bmj.d5928 · Cited by 33,817 · see citing works

Mortality from Coronary Heart Disease in Subjects with Type 2 Diabetes and in Nondiabetic Subjects with and without Prior Myocardial Infarction

Haffner, S. M., Lehto, S., Rönnemaa, T., Pyörälä, K., & Laakso, M. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807233390404 · Cited by 7,000 · see citing works

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

Dormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67528-9 · Cited by 4,129 · see citing works

The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation

Ricote, M., Li, A. C., Willson, T. M., Kelly, C. J., & Glass, C. K. (1998) · Nature · doi:10.1038/34178 · Cited by 3,525 · see citing works

Prediabetes: a high-risk state for diabetes development

Tabák, A. G., Herder, C., Rathmann, W., Brunner, E. J., & Kivimäki, M. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60283-9 · Cited by 2,958 · see citing works

Pioglitazone after Ischemic Stroke or Transient Ischemic Attack

Kernan, W. N., Viscoli, C. M., Furie, K. L., Young, L. H., Inzucchi, S. E., Gorman, M., Guarino, P. D., Lovejoy, A. M., Peduzzi, P. N., Conwit, R., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1506930 · Cited by 1,127 · see citing works

Comparison of Pioglitazone vs Glimepiride on Progression of Coronary Atherosclerosis in Patients With Type 2 Diabetes: The PERISCOPE Randomized Controlled Trial

Nissen, S. E., Nicholls, S. J., Wolski, K., Nesto, R., Kupfer, S., Perez, A., Jure, H., De Larochellière, R., Staniloae, C. S., Mavromatis, K., et al. (2008) · JAMA · doi:10.1001/jama.299.13.1561 · Cited by 850 · see citing works

Thiazolidinedione Use, Fluid Retention, and Congestive Heart Failure

Nesto, R. W., Bell, D. S. H., Bonow, R. O., Fonseca, V. A., Grundy, S. M., Horton, E. S., Winter, M. L., Porte, D., Semenkovich, C. F., Smith, S. E., et al. (2003) · Circulation · doi:10.1161/01.cir.0000103683.99399.7e · Cited by 831 · see citing works

Preferred reporting items for systematic reviews and meta-analyses (PRISMA) statement and publication bias

Knobloch, K., Yoon, U., & Vogt, P. M. (2011) · Journal of Cranio-Maxillofacial Surgery · doi:10.1016/j.jcms.2010.11.001 · Cited by 802 · see citing works

A Comparison of Lipid and Glycemic Effects of Pioglitazone and Rosiglitazone in Patients With Type 2 Diabetes and Dyslipidemia

Goldberg, R. B., Kendall, D. M., Deeg, M. A., Buse, J. B., Zagar, A. J., Pinaire, J. A., Tan, M. H., Khan, M. A., Perez, A. T., Jacober, S. J., et al. (2005) · Diabetes Care · doi:10.2337/diacare.28.7.1547 · Cited by 790 · see citing works

Pioglitazone for Diabetes Prevention in Impaired Glucose Tolerance

DeFronzo, R. A., Tripathy, D., Schwenke, D. C., Banerji, M., Bray, G. A., Buchanan, T. A., Clement, S. C., Henry, R. R., Hodis, H. N., Kitabchi, A. E., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1010949 · Cited by 752 · see citing works

Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients

Miyazaki, Y., Mahankali, A., Matsuda, M., Mahankali, S., Hardies, J., Cusi, K., Mandarino, L. J., & DeFronzo, R. A. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.6.8567 · Cited by 726 · see citing works

Effect of Pioglitazone Compared With Glimepiride on Carotid Intima-Media Thickness in Type 2 Diabetes: A Randomized Trial

Mazzone, T., Meyer, P. M., Feinstein, S. B., Davidson, M. H., Kondos, G. T., D’Agostino, R. B., Perez, A., Provost, J.-C., & Haffner, S. M. (2006) · JAMA · doi:10.1001/jama.296.21.joc60158 · Cited by 674 · see citing works

Vascular complications in diabetes mellitus: the role of endothelial dysfunction

Schalkwijk, C. G., & Stehouwer, C. D. A. (2005) · Clinical Science · doi:10.1042/cs20050025 · Cited by 657 · see citing works

Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial

Vaccaro, O., Masulli, M., Nicolucci, A., Bonora, E., Del Prato, S., Maggioni, A. P., Rivellese, A. A., Squatrito, S., Giorda, C. B., Sesti, G., et al. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30317-0 · Cited by 292 · see citing works

Efficacy and Safety of Pioglitazone Versus Metformin in Patients with Type 2 Diabetes Mellitus: A Double-Blind, Randomized Trial

Schernthaner, G., Matthews, D. R., Charbonnel, B. H., Markolf Hanefeld, E., & Brunetti, P. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030861 · Cited by 268 · see citing works

Dose-Response Effect of Pioglitazone on Insulin Sensitivity and Insulin Secretion in Type 2 Diabetes

Miyazaki, Y., Matsuda, M., & DeFronzo, R. A. (2002) · Diabetes Care · doi:10.2337/diacare.25.3.517 · Cited by 236 · see citing works

One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes

Hanefeld, M., Brunetti, P., Schernthaner, G. H., Matthews, D. R., Charbonnel, B. H., & on behalf of the QUARTET Study Group (2004) · Diabetes Care · doi:10.2337/diacare.27.1.141 · Cited by 230 · see citing works

Diabetes Mellitus, Prediabetes, and Incidence of Subclinical Myocardial Damage

Selvin, E., Lazo, M., Chen, Y., Shen, L., Rubin, J., McEvoy, J. W., Hoogeveen, R. C., Sharrett, A. R., Ballantyne, C. M., & Coresh, J. (2014) · Circulation · doi:10.1161/circulationaha.114.010815 · Cited by 226 · see citing works

Protection of the kidney by thiazolidinediones: An assessment from bench to bedside

Sarafidis, P. A., & Bakris, G. L. (2006) · Kidney International · doi:10.1038/sj.ki.5001620 · Cited by 221 · see citing works

Pioglitazone and cardiovascular outcomes in patients with insulin resistance, pre-diabetes and type 2 diabetes: A systematic review and meta-analysis

Liao, H.-W., Saver, J. L., Wu, Y.-L., Chen, T.-H., Lee, M., & Ovbiagele, B. (2017) · BMJ Open · doi:10.1136/bmjopen-2016-013927 · Cited by 198 · see citing works

Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study

Matthews, D. R., Charbonnel, B. H., Markolf Hanefeld, E., Brunetti, P., & Schernthaner, G. (2004) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.478 · Cited by 174 · see citing works

The prevalence of multiple diabetes‐related complications

Morgan, C. L., Currie, C. J., Stott, N. C. H., Smithers, M., Butler, C., & Peters, J. R. (2000) · Diabetic Medicine · doi:10.1046/j.1464-5491.2000.00222.x · Cited by 145 · see citing works

The PROactive study: some answers, many questions

Yki‐Järvinen, H. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67504-6 · Cited by 142 · see citing works

Insulin Sensitivity, Insulinemia, and Coronary Artery Disease

Rewers, M., Zaccaro, D. J., D’Agostino, R., Haffner, S. M., Saad, M. F., Selby, J. V., Bergman, R. N., Savage, P. J., & for the Insulin Resistance Atherosclerosis Study Investigators (2004) · Diabetes Care · doi:10.2337/diacare.27.3.781 · Cited by 135 · see citing works

Pioglitazone and the secondary prevention of cardiovascular disease. A meta-analysis of randomized-controlled trials

de Jong, M., van der Worp, H. B., van der Graaf, Y., Visseren, F. L. J., & Westerink, J. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0617-4 · Cited by 132 · see citing works

Expression and Function of Peroxisome Proliferator–Activated Receptor-γ in Mesangial Cells

Nicholas, S. B., Kawano, Y., Wakino, S., Collins, A. R., & Hsueh, W. A. (2001) · Hypertension · doi:10.1161/01.hyp.37.2.722 · Cited by 126 · see citing works

Peroxisome Proliferator-Activated Receptor-γ Ligands Inhibit TGF-β1-Induced Fibronectin Expression in Glomerular Mesangial Cells

Guo, B., Koya, D., Isono, M., Sugimoto, T., Kashiwagi, A., & Haneda, M. (2004) · Diabetes · doi:10.2337/diabetes.53.1.200 · Cited by 122 · see citing works

Pioglitazone Slows Progression of Atherosclerosis in Prediabetes Independent of Changes in Cardiovascular Risk Factors

Saremi, A., Schwenke, D. C., Buchanan, T. A., Hodis, H. N., Mack, W. J., Banerji, M., Bray, G. A., Clement, S. C., Henry, R. R., Kitabchi, A. E., et al. (2013) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.112.300346 · Cited by 101 · see citing works

Addition of pioglitazone or bedtime insulin to maximal doses of sulfonylurea and metformin in type 2 diabetes patients with poor glucose control: a prospective, randomized trial

Aljabri, K., Kozak, S. E., & Thompson, D. M. (2004) · The American Journal of Medicine · doi:10.1016/j.amjmed.2003.07.023 · Cited by 98 · see citing works

A Randomized Comparison of Pioglitazone to Inhibit Restenosis After Coronary Stenting in Patients With Type 2 Diabetes

Nishio, K., Sakurai, M., Kusuyama, T., Shigemitsu, M., Fukui, T., Kawamura, K., Itoh, S., Konno, N., & Katagiri, T. (2006) · Diabetes Care · doi:10.2337/diacare.29.01.06.dc05-1170 · Cited by 97 · see citing works

Variance-modeled posterior inference of microarray data: detecting gene-expression changes in 3T3-L1 adipocytes

Hsiao, A., Worrall, D. S., Olefsky, J. M., & Subramaniam, S. (2004) · Bioinformatics · doi:10.1093/bioinformatics/bth371 · Cited by 89 · see citing works

The progressive pathway of microalbuminuria: from early marker of renal damage to strong cardiovascular risk predictor

Cerasola, G., Cottone, S., & Mulè, G. (2010) · Journal of Hypertension · doi:10.1097/hjh.0b013e32833ec377 · Cited by 79 · see citing works

A Prospective, Multicenter, Randomized Trial to Assess Efficacy of Pioglitazone on In-Stent Neointimal Suppression in Type 2 Diabetes

Takagi, T., Okura, H., 小林, 芳., Kataoka, T., Taguchi, H., Toda, I., Tamita, K., Yamamuro, A., Sakanoue, Y., Ito, A., et al. (2009) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2009.04.007 · Cited by 65 · see citing works

Effects of Pioglitazone for Secondary Stroke Prevention in Patients with Impaired Glucose Tolerance and Newly Diagnosed Diabetes: The J-SPIRIT Study

Tanaka, R., Yamashiro, K., Okuma, Y., Shimura, H., Nakamura, S., Ueno, Y., Tanaka, Y., Miyamoto, N., Tomizawa, Y., Nakahara, T., et al. (2015) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.30007 · Cited by 56 · see citing works

Long‐term Safety of Pioglitazone versus Glyburide in Patients with Recently Diagnosed Type 2 Diabetes Mellitus

Jain, R., Osei, K., Kupfer, S., Perez, A. T., Zhang, J., & Lannon, M. (2006) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.26.10.1388 · Cited by 47 · see citing works

Effects of Pioglitazone on Macrovascular Events in Patients with Type 2 Diabetes Mellitus at High Risk of Stroke: The PROFIT-J Study

Yoshii, H., Onuma, T., Yamazaki, T., Watada, H., Matsuhisa, M., Matsumoto, M., Kitagawa, K., Kitakaze, M., Yamasaki, Y., & Kawamori, R. (2014) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.21626 · Cited by 47 · see citing works

Biphasic Vasodilator Action of Troglitazone on the Renal Microcirculation

Arima, S., Kohagura, K., Takeuchi, K., Taniyama, Y., Sugawara, A., Ikeda, Y., Abe, M., Omata, K., & Ito, S. (2002) · Journal of the American Society of Nephrology · doi:10.1681/asn.v132342 · Cited by 45 · see citing works

Risk of Stroke with Thiazolidinediones: A Ten-Year Nationwide Population-Based Cohort Study

Lu, C.-J., Sun, Y., Muo, C., Chen, R.-C., Chen, P., & Hsu, C. Y. (2013) · Cerebrovascular Diseases · doi:10.1159/000353679 · Cited by 41 · see citing works

Renoprotection Provided by Losartan in Combination with Pioglitazone Is Superior to Renoprotection Provided by Losartan Alone in Patients with Type 2 Diabetic Nephropathy

Jin, H. M., & Pan, Y. (2007) · Kidney & Blood Pressure Research · doi:10.1159/000104089 · Cited by 38 · see citing works

Pioglitazone reduces urinary protein and urinary transforming growth factor-beta excretion in patients with type 2 diabetes and overt nephropathy.

Katavetin, P., Eiam‐Ong, S., & Suwanwalaikorn, S. (2006) · PubMed · Cited by 30 · see citing works

Pioglitazone and cause-specific risk of mortality in patients with type 2 diabetes: extended analysis from a European multidatabase cohort study

Strongman, H., Christopher, S., Majak, M., Williams, R., Bahmanyar, S., Linder, M., Heintjes, E. M., Bennett, D., Korhonen, P. A., & Hoti, F. J. (2018) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2017-000481 · Cited by 30 · see citing works

Long-term effects of pioglitazone in Japanese patients with type 2 diabetes without a recent history of macrovascular morbidity

Kaku, K., Daida, H., Kashiwagi, A., Yamashina, A., Yamazaki, T., Momomura, S., Iwase, T., Yamasaki, Y., Nagatsuka, K., Kitagawa, K., et al. (2009) · Current Medical Research and Opinion · doi:10.1185/03007990903328124 · Cited by 27 · see citing works

Insulin Resistance and Endothelin: Another Pathway for Renal Injury in Patients With the Cardiometabolic Syndrome?

Sarafidis, P. A., & Lasaridis, A. N. (2008) · Journal of the CardioMetabolic Syndrome · doi:10.1111/j.1559-4572.2008.00009.x · Cited by 25 · see citing works

Impact of treatment with pioglitazone on stroke outcomes: A real‐world database analysis

Morgan, C. L., Inzucchi, S. E., Puelles, J., Jenkins‐Jones, S., & Currie, C. J. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13344 · Cited by 23 · see citing works

Pioglitazone reduces urinary albumin excretion in renin−angiotensin system inhibitor-treated type 2 diabetic patients with hypertension and microalbuminuria: the APRIME study

Morikawa, A., Ishizeki, K., Iwashima, Y., Yokoyama, H., Muto, E., Oshima, E., SEKIGUCHI, M., Miura, T., Itoh, H., & Haneda, M. (2011) · Clinical and Experimental Nephrology · doi:10.1007/s10157-011-0512-3 · Cited by 21 · see citing works

Effect of pioglitazone on decreasing of proteinuria in type 2 diabetic patients with nephropathy

pourshabanan, P., Momeni, A., Mahmoudnia, L., & Kheiri, S. (2018) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2018.04.013 · Cited by 20 · see citing works

Pioglitazone Increases Circulating MicroRNA-24 With Decrease in Coronary Neointimal Hyperplasia in Type 2 Diabetic Patients – Optical Coherence Tomography Analysis –

Hong, S. J., Choi, S. C., Cho, J. Y., Joo, H. J., Park, J. H., Yu, C. W., & Lim, D. (2015) · Circulation Journal · doi:10.1253/circj.cj-14-0964 · Cited by 18 · see citing works

Effects of Low Dose Pioglitazone on Restenosis and Coronary Atherosclerosis in Diabetic Patients Undergoing Drug Eluting Stent Implantation

Lee, H. W., Lee, H. C., Kim, B. W., Yang, M., Park, J. S., Oh, J. H., Choi, J. H., Cha, K. S., Hong, T. J., Kim, S.-P., et al. (2013) · Yonsei Medical Journal · doi:10.3349/ymj.2013.54.6.1313 · Cited by 16 · see citing works

Efficacy and safety of pioglitazone in patients with ST elevation myocardial infarction treated with primary stent implantation

Kaneda, H., Shiono, T., Miyashita, Y., Takahashi, S., Taketani, Y., Domae, H., Matsumi, J., Mizuno, S., Minami, Y., Sugitatsu, K., et al. (2009) · Heart · doi:10.1136/hrt.2008.162842 · Cited by 15 · see citing works

The effect of hydrochloride pioglitazone on urinary 8-hydroxy -deoxyguanosine excretion in type 2 diabetics

Wang, Y.-F., Ye, S., Hu, Y., Zhao, L., & Zheng, M. (2012) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2012.08.004 · Cited by 12 · see citing works

Effect of pioglitazone on cardiometabolic profiles and safety in patients with type 2 diabetes undergoing percutaneous coronary artery intervention: a prospective, multicenter, randomized trial

On behalf of the Pioglitazone Reduce Inflammation and Restenosis with and without Drug Eluting Stent (PRIDE) Study Investigators, Tanaka, A., Komukai, S., Shibata, Y., Yokoi, H., Iwasaki, Y., Kawasaki, T., Horiuchi, K., Nakao, K., Ueno, T., et al. (2018) · Heart and Vessels · doi:10.1007/s00380-018-1143-3 · Cited by 11 · see citing works

Cardiovascular Outcomes in Patients With Previous Myocardial Infarction and Mild Diabetes Mellitus Following Treatment With Pioglitazone

Asakura, M., Kim, J., Asanuma, H., Nakama, Y., Tsukahara, K., Higashino, Y., Ishikawa, T., Koba, S., Tsujimoto, M., Himeno, H., et al. (2018) · EClinicalMedicine · doi:10.1016/j.eclinm.2018.09.006 · Cited by 10 · see citing works

2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes.

Marx, N., Federici, M., Schütt, K., Müller-Wieland, D., Ajjan, R. A., Antunes, M. J., Christodorescu, R. M., Crawford, C., Di Angelantonio, E., Eliasson, B., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad192 · Cited by 1,642 · see citing works

The complex link between NAFLD and type 2 diabetes mellitus - mechanisms and treatments

Targher, G., Corey, K. E., Byrne, C. D., & Roden, M. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00448-y · Cited by 850 · see citing works

American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update.

Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507 · see citing works

Metabolic liver disease in diabetes – From mechanisms to clinical trials

Dewidar, B., KAHL, S., Pafili, K., & Roden, M. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154299 · Cited by 160 · see citing works

Rethinking pioglitazone as a cardioprotective agent: a new perspective on an overlooked drug

Nesti, L., Tricò, D., Mengozzi, A., & Natali, A. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01294-7 · Cited by 125 · see citing works

Comparing the effects of tofogliflozin and pioglitazone in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus (ToPiND study): a randomized prospective open-label controlled trial

Yoneda, M., Honda, Y., Ogawa, Y., Kessoku, T., Kobayashi, T., Imajo, K., Ozaki, A., Nogami, A., Taguri, M., Yamanaka, T., et al. (2021) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2020-001990 · Cited by 100 · see citing works

Antioxidant Phytochemicals as Potential Therapy for Diabetic Complications

Akpoveso, O.-O. P., Ubah, E. E., & Obasanmi, G. (2023) · Antioxidants · doi:10.3390/antiox12010123 · Cited by 90 · see citing works

13. Older Adults: Standards of Care in Diabetes—2026

American Diabetes Association Professional Practice Committee for Diabetes*, Bajaj, M., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Briggs Early, K., ChallaSivaKanaka, S., et al. (2026) · Diabetes Care · doi:10.2337/dc26-s013 · Cited by 87 · see citing works

Pharmacological Approaches to Nonalcoholic Fatty Liver Disease: Current and Future Therapies

Genua, I., & Cusi, K. J. (2024) · Diabetes Spectrum · doi:10.2337/dsi23-0012 · Cited by 74 · see citing works

Nonalcoholic fatty liver disease or metabolic dysfunction‐associated fatty liver disease diagnoses and cardiovascular diseases: From epidemiology to drug approaches

Dongiovanni, P., Paolini, E., Corsini, A., Sirtori, C. R., & Ruscica, M. (2021) · European Journal of Clinical Investigation · doi:10.1111/eci.13519 · Cited by 70 · see citing works

Effect of Glucose Levels on Cardiovascular Risk

Poznyak, A. V., Litvinova, L. S., Poggio, P., Sukhorukov, V. N., & Orekhov, A. N. (2022) · Cells · doi:10.3390/cells11193034 · Cited by 73 · see citing works

Nuclear receptors in podocyte biology and glomerular disease

Agrawal, S., He, C., & Tharaux, P. (2020) · Nature Reviews Nephrology · doi:10.1038/s41581-020-00339-6 · Cited by 57 · see citing works

MASLD treatment—a shift in the paradigm is imminent

Machado, M. V. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1316284 · Cited by 51 · see citing works

Effects of glucose‐lowering agents on cardiovascular and renal outcomes in subjects with type 2 diabetes: An updated meta‐analysis of randomized controlled trials with external adjudication of events

Mannucci, E., Gallo, M., Giaccari, A., Candido, R., Pintaudi, B., Targher, G., Monami, M., & Diabetes, T. S. J. P. F. I. G. O. T. O. T. 2. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14888 · Cited by 44 · see citing works

The Many Facets of PPAR-γ Agonism in Obesity and Associated Comorbidities: Benefits, Risks, Challenges, and Future Directions

Kounatidis, D. C., Vallianou, N. G., Rebelos, E., Kouveletsou, M., Kontrafouri, P., Eleftheriadou, I., Diakoumopoulou, E., Karampela, Ι., Tentolouris, N., & Dalamaga, Μ. (2025) · Current Obesity Reports · doi:10.1007/s13679-025-00612-4 · Cited by 35 · see citing works

Efficacy and safety of novel thiazolidinedione lobeglitazone for managing type-2 diabetes a meta-analysis

Dutta, D., Bhattacharya, S., Kumar, M., Datta, P. K., Mohindra, R., & Sharma, M. (2022) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2022.102697 · Cited by 33 · see citing works

Peroxisome proliferator activated receptor-γ agonist pioglitazone improves vascular and metabolic dysfunction in systemic lupus erythematosus

Hasni, S., Temesgen‐Oyelakin, Y., Davis, M., Chu, J., Poncio, E., Naqi, M., Gupta, S., Wang, X., Oliveira, C. B., Claybaugh, D., et al. (2022) · Annals of the Rheumatic Diseases · doi:10.1136/ard-2022-222658 · Cited by 24 · see citing works

Thiazolidinediones and Glucagon‐Like Peptide‐1 Receptor Agonists and the Risk of Nonalcoholic Fatty Liver Disease: A Cohort Study

Dalem, J. D. R.-V., Driessen, J. H. M., Burden, A. M., Stehouwer, C. D. A., Klungel, O. H., de Vries, F., & Brouwers, M. C. G. J. (2021) · Hepatology · doi:10.1002/hep.32012 · Cited by 23 · see citing works

Effects of pioglitazone on cardiovascular events and all-cause mortality in patients with type 2 diabetes: A meta-analysis of randomized controlled trials

Mannucci, E., Giaccari, A., Gallo, M., Targher, G., Pintaudi, B., Candido, R., & Monami, M. (2021) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2021.12.006 · Cited by 21 · see citing works

Pioglitazone, SGLT2 inhibitors and their combination for primary prevention of cardiovascular disease and heart failure in type 2 diabetes: Real-world evidence from a nationwide cohort database

Lo, S., Kornelius, E., Liao, P., Huang, J., Yang, Y., & Huang, C. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110685 · Cited by 21 · see citing works

Association of Pioglitazone With Major Adverse Cardiovascular Events, All-Cause Mortality, and Heart Failure Hospitalizations: A Systematic Review

Sheikh, I. M., Hassan, O. A., Adam, S. M., Ali, A. I., Ogedegbe, O. J., Tabowei, G., Barbarawi, A., Yussuf, F. M., & Nor, M. A. (2023) · Cureus · doi:10.7759/cureus.46911 · Cited by 28 · see citing works

Protective effects of pioglitazone in renal ischemia–reperfusion injury (RIRI): focus on oxidative stress and inflammation

Golmohammadi, M., Ivraghi, M. S., Hasan, E. K., Huldani, H., Zamanian, M. Y., Rouzbahani, S., Mustafa, Y. F., Al-Hasnawi, S. S., Alazbjee, A. A. A., Khalajimoqim, F., et al. (2024) · Clinical and Experimental Nephrology · doi:10.1007/s10157-024-02525-3 · Cited by 24 · see citing works

A Review of the Epidemiology, Pathophysiology, and Efficacy of Anti-diabetic Drugs Used in the Treatment of Nonalcoholic Fatty Liver Disease

Manka, P. P., Kaya, E., Canbay, A. E., & Syn, W. (2021) · Digestive Diseases and Sciences · doi:10.1007/s10620-021-07206-9 · Cited by 20 · see citing works

Lobeglitazone, a novel thiazolidinedione, for secondary prevention in patients with ischemic stroke: a nationwide nested case-control study

Yoo, J., Jeon, J., Baik, M., & Kim, J. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01841-4 · Cited by 19 · see citing works

Diabetes and cardiovascular disease in older adults

Bilal, A., & Pratley, R. E. (2024) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.15259 · Cited by 18 · see citing works

Tackling type 2 diabetes-associated cardiovascular and renal comorbidities: a key challenge for drug development

Adeghate, E. A., Kalász, H., Jaberi, S. A., Adeghate, J. O., & Tekes, K. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2021.1865914 · Cited by 19 · see citing works

Pioglitazone in diabetic kidney disease: forgotten but not gone

Papaetis, G. S. (2022) · Archives of Medical Science - Atherosclerotic Diseases · doi:10.5114/amsad/151046 · Cited by 15 · see citing works

Instituting a successful discharge plan for patients with type 2 diabetes: challenges and solutions

Demidowich, A. P., Batty, K., & Zilbermint, M. (2022) · Diabetes Spectrum · doi:10.2337/dsi22-0013 · Cited by 15 · see citing works

Role of anti-diabetic medications in the management of MASLD

Isaacs, S. D., Farrelly, F. V., & Brennan, P. (2025) · Frontline Gastroenterology · doi:10.1136/flgastro-2024-102856 · Cited by 17 · see citing works

The efficacy of pioglitazone for renal protection in diabetic kidney disease

Ho, C.-C., Yang, Y., Huang, C., Lo, S., Wang, Y., & Kornelius, E. (2022) · PLoS ONE · doi:10.1371/journal.pone.0264129 · Cited by 15 · see citing works

Pioglitazone for primary stroke prevention in Asian patients with type 2 diabetes and cardiovascular risk factors: a retrospective study

Hung, Y., Chiu, L., Huang, H., & Bau, D. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01056-x · Cited by 13 · see citing works

Polycystic ovary syndrome: A review of diagnosis and management, with special focus on atherosclerotic cardiovascular disease prevention

Myerson, M. L., Paparodis, R. D., Block, R., Karalis, D. G., Mintz, G. L., Brinton, E. A., & Wild, R. A. (2024) · Journal of clinical lipidology · doi:10.1016/j.jacl.2024.04.131 · Cited by 12 · see citing works

Diagnosis and management of type 2 diabetes mellitus in patients with ischaemic heart disease and acute coronary syndromes - a review of evidence and recommendations

Shah, M. U., Roebuck, A., Srinivasan, B., Ward, J. K., Squires, P. E., Hills, C. E., & Lee, K. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1499681 · Cited by 13 · see citing works

Current gaps in management and timely referral of cardiorenal complications among people with type 2 diabetes mellitus in the Middle East and African countries: Expert recommendations

Sönmez, A., Sabbour, H. M., Echtay, A. S., Rahmah, A. M., Alhozali, A. M., Sabaan, F. S. A., Haddad, F., Iraqi, H., Elebrashy, I., Assaad, S. N., et al. (2022) · Journal of Diabetes · doi:10.1111/1753-0407.13266 · Cited by 14 · see citing works

Cardiovascular Outcome Trials with Glucose-Lowering Drugs

Thethi, T. K., Bilal, A., & Pratley, R. E. (2021) · Current Cardiology Reports · doi:10.1007/s11886-021-01505-3 · Cited by 11 · see citing works

Genetics and Clinical Characteristics of PPARγ Variant-Induced Diabetes in a Chinese Han Population

Gong, S., Han, X., Li, M., Cai, X., Liu, W., Luo, Y., Zhang, S.-M., Zhou, L., Ma, Y., Huang, X., et al. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.677130 · Cited by 10 · see citing works

Cytotoxicity and toxicoproteomics analysis of thiazolidinedione exposure in human‐derived cardiomyocytes

Al-Sultan, A., Rattray, Z., & Rattray, N. J. W. (2024) · Journal of Applied Toxicology · doi:10.1002/jat.4613 · Cited by 9 · see citing works

Development and validation of nomograms for predicting cardiovascular disease risk in patients with prediabetes and diabetes

Zhao, L., Kang, S., & Kang, H. (2024) · Scientific Reports · doi:10.1038/s41598-024-71904-3 · Cited by 9 · see citing works

Rethinking the role of pioglitazone in modern diabetology as a cardiorenoprotective agent

Салухов, В. В., & Анатольевна, К. Е. (2022) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2022-16-10-10-21 · Cited by 10 · see citing works

Introduction of Diabetes Mellitus and Future Prospects of Natural Products on Diabetes Mellitus

Chen, H., & Li, R. (2021) · Springer eBooks · doi:10.1007/978-981-15-8791-7_1 · Cited by 7 · see citing works

Synergistically improved cardiovascular outcomes in type 2 diabetes mellitus patients with combined treatment of SGLT-2 inhibitors and pioglitazone

Li, Y., Wang, C., Liu, C., Yen, C., Wu, V. C., Huang, E. J.-C., Lee, C., & Hsiao, C.-C. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1420485 · Cited by 6 · see citing works

Understanding patient cost-sharing thresholds for diabetes treatment attributes via a discrete choice experiment

Panchal, R., Nguyen, D. T., Ghule, P., Li, N., Giannouchos, T. V., Pan, R. J., BISKUPIAK, J. E., Britton, L., Nohavec, R., Slager, S. L., et al. (2023) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2023.29.2.139 · Cited by 6 · see citing works

Association between hypoglycemic agent use and the risk of occurrence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus

Jung, C., Park, S., & Kim, H. (2023) · PLoS ONE · doi:10.1371/journal.pone.0294423 · Cited by 6 · see citing works

Prediabetes and CKD: Does a causal relationship exist

Rico-Fontalvo, J. E., Soler, M. J., Daza-Arnedo, R., Navarro‐Blackaller, G., Medina-González, R., Yánez, T. R., Cardona-Blanco, M., Cabrales, J., Uparrela-Gulfo, I., & Chavez-Iñiguez, J. S. (2024) · Nefrología · doi:10.1016/j.nefro.2024.06.008 · Cited by 5 · see citing works

Is fluid retention a cardiovascular risk factor?

Blankfield, R. P. (2024) · Clinical Hemorheology and Microcirculation · doi:10.3233/ch-242128 · Cited by 5 · see citing works

Pioglitazone enhances proteinuria reduction in complicated pediatric nephrotic syndrome

Hunley, T. E., Hidalgo, G., Ng, K. H., Shirai, Y., Miura, K., Beng, H. M., Wu, Q. E., Hattori, M., & Smoyer, W. E. (2022) · Pediatric Nephrology · doi:10.1007/s00467-022-05637-8 · Cited by 5 · see citing works

Contemporary choice of glucose lowering agents in heart failure patients with type 2 diabetes

Katsiki, N., Kazakos, K., & Triposkiadis, F. K. (2022) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2022.2143263 · Cited by 6 · see citing works

A Saudi Heart Association Position Statement on Cardiovascular Diseases and Diabetes Mellitus

AlHabeeb, W., Elasfar, A., Kinsara, A. J., Aljizeeri, A. H., Jelaidan, I., Alghalayini, K. W., AlKheraiji., M. F., Akbar, M. A. J., Lawand, S., Alyousif, S. M., et al. (2024) · Journal of the Saudi Heart Association · doi:10.37616/2212-5043.1407 · Cited by 6 · see citing works

Glucocorticoid- and pioglitazone-induced proteinuria reduction in experimental NS both correlate with glomerular ECM modulation

Bhayana, S., Dougherty, J. A., Kamigaki, Y., Agrawal, S., Wijeratne, S., Fitch, J., Waller, A. P., Wolfgang, K. J., White, P., Kerlin, B. A., et al. (2023) · iScience · doi:10.1016/j.isci.2023.108631 · Cited by 4 · see citing works

From bench to bedside: targeting ferroptosis and mitochondrial damage in the treatment of diabetic cardiomyopathy

Liu, B., Jin, Q., Sun, Y., Yang, Z. M., Meng, P., Zhang, X., Chen, Q., Gan, P., Zhao, T., He, J., et al. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1563362 · Cited by 7 · see citing works

Cardioprotective Effects of Pioglitazone in Type 2 Diabetes

Tripathy, D., Solis‐Herrera, C., & Ryder, R. E. J. (2021) · Diabetes Spectrum · doi:10.2337/ds20-0078 · Cited by 5 · see citing works

Thiazolidinediones for people with chronic kidney disease and diabetes

Natale, P., Green, S. C., Tunnicliffe, D. J., Pellegrino, G., Toyama, T., Sarafidis, P. A., Strippoli, G. F., & Transplant, S. B. C. K. A. (2025) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd015907.pub2 · Cited by 3 · see citing works

Effect of Medications for Type 2 Diabetes on Cardiovascular Events and Mortality: A Comprehensive Pairwise and Network Meta‐Analysis

Silverii, G. A., Velardi, V., Marinelli, C., Lax, A., Monami, M., & Mannucci, E. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71128 · Cited by 3 · see citing works

A nem alkoholos zsírmájbetegség és a 2-es típusú cukorbetegség.

Pár, A., Wittmann, I., & Pár, G. (2022) · Orvosi Hetilap · doi:10.1556/650.2022.32480 · Cited by 3 · see citing works

Biomarkers and therapies to target endothelial dysfunction in type 2 diabetes: moving a step forward

Chee, Y. J., Loh, W. J., & Dalan, R. (2025) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000933 · Cited by 2 · see citing works

Cardiovascular adverse effects of common non-oncologic medications: from mechanisms to clinical management

Bahit, M. C., Agudo-Quílez, P., Zamorano, J. L., & Gibson, C. M. (2026) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvag007 · Cited by 2 · see citing works

Prevention of Cardiovascular Disease in Patients with Chronic Kidney Disease

Lo, R. H., & Glassock, R. J. (2020) · Contemporary cardiology · doi:10.1007/978-3-030-56279-3_25 · Cited by 2 · see citing works

Cardiovascular disease in metabolic-associated fatty liver disease

Adams, L. A. (2023) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000803 · Cited by 2 · see citing works

Modern strategies for the treatment of type 2 diabetes in patients with stable coronary artery disease. Old goals, new opportunities (literature review)

Гришаев, С. Л., Cherkashin, D. V., Салухов, В. В., & Alanichev, A. E. (2024) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2024-5689 · Cited by 2 · see citing works

Cytotoxicity and Toxicoproteomic Analysis of Pioglitazone Exposure in Human-derived CardiomyocytesPreprint

Sultan, A. A., Rattray, Z., & Rattray, N. J. W. (2023) · Research Square · doi:10.21203/rs.3.rs-3410461/v1 · Cited by 2 · see citing works

Prediabetes and CKD: Does a causal relationship exist

Rico-Fontalvo, J. E., Soler, M. J., Daza-Arnedo, R., Navarro‐Blackaller, G., Medina-González, R., Yánez, T. R., Cardona-Blanco, M., Cabrales, J., Uparrela-Gulfo, I., & Chavez-Iñiguez, J. S. (2024) · Nefrología (English Edition) · doi:10.1016/j.nefroe.2024.11.005 · Cited by 1 · see citing works

Identification of drug combinations to reduce the risk of pioglitazone-related bladder cancer using the FDA adverse event reporting system database

Yang, J., Zhao, H., Yan, M.-M., Xiang, Z., Zhang, Q., Chen, H.-Y., & Qiu, X. (2025) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2025.2492744 · Cited by 1 · see citing works

Fixed-dose combinations of hypoglycemic drugs: potential of alogliptin/pioglitazone in type 2 diabetes mellitus: a review

Butranova, O. I., Zyryanov, S. K., Melnikova, A. R., & Matsepuro, A. E. (2025) · Terapevticheskii arkhiv · doi:10.26442/00403660.2025.08.203345 · Cited by 1 · see citing works

Cholesterol efflux in HIV-associated atherosclerosis: mechanisms and targets

Lu, E., Chidambaram, V., Kumar, A., Aparicio, H. C., Golzar, Y., Pyslar, N., Mehta, J. L., & Karakousis, P. C. (2025) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2025.08.003 · Cited by 1 · see citing works

Similar incidence of stroke with SGLT2 inhibitors and GLP-1 receptor agonists in real-world cohort studies among patients with type 2 diabetes

Scheen, A. J. (2023) · Diabetes Epidemiology and Management · doi:10.1016/j.deman.2023.100179 · Cited by 1 · see citing works

To Conduct a Prospective Study on Pioglitazone Induced Kidney Injury in Tertiary Care Hospital

Archana, B., Vishwada, P., Charani, Y. S. S., & Shri, D. S. (2024) · Journal of Drug Delivery and Therapeutics · doi:10.22270/jddt.v14i1.6183 · Cited by 1 · see citing works

Advances in Cardiology in 2023

Bendiab, N. T., Khedim, N., Kazi-Tani, D., Bensalah, M., Sari, A., & Djafour, S. (2024) · International Journal of Medical Science and Clinical Research Studies · doi:10.47191/ijmscrs/v4-i01-15 · Cited by 1 · see citing works

What is the role of pioglitazone for patients with type 2 diabetes in value-based care settings?

Bush, A., Benny, T., Hale, G. M., & Seamon, M. J. (2024) · Drugs & Therapy Perspectives · doi:10.1007/s40267-024-01052-1 · Cited by 1 · see citing works

Pioglitazone - the forgotten drug with multidirectional action

Aab, A., & Zarańska, J. (2023) · Journal of Education Health and Sport · doi:10.12775/jehs.2023.24.01.001

Effect of pioglitazone on proteinuria and cardiovascular events in patients with diabetic nephropathy

Hejazian, S. M., Vahed, S. Z., Haghighi, N. K., Niknafs, B., & Farnood, F. (2023) · Journal of Renal Injury Prevention · doi:10.34172/jrip.2023.32186

Efficacy and Safety of Novel Thiazolidinedione Rivoglitazone in Type-2 Diabetes a Meta-Analysis

Dutta, D., Kadian, J., Maisnam, I., Kumar, A., Bhattacharya, S., & Sharma, M. (2023) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_17_23

Nonalcoholic fatty liver disease is a risk factor for cardiovascular disease

Li, Q. I. N., JunRu, W. U., YuQing, L. I. U., YingXuan, G. O. N. G., & JingJing, C. A. I. (2024) · Scientia Sinica Vitae · doi:10.1360/ssv-2024-0098

Diabetes-Induced Cardiomyopathy: Updates in Epidemiology, Prevention, and Management

Adeghate, E. A., Mohsin, S., Amar, A., AlAmry, S., Alotaiba, M. K., Oyeleye, O. A., & Singh, J. (2024) · IntechOpen eBooks · doi:10.5772/intechopen.1006679

Efficacy and safety of pioglitazone versus dapagliflozin as an add-on to metformin and alogliptin combination therapy: the EPIDOTE study

Kim, K., Ko, S., Yun, J., Lee, K. W., Kim, E., Jeong, I., Kim, J. H., Kim, S. Y., Won, K. C., Kim, M.-K., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-30882-w

Atherosclerotic cardiovascular disease and type 2 diabetes mellitus in elderly patients: risk management (review)

Bogomolov, A. N., Николаевна, К. О., Kozlov, K. L., & Golikova, E. N. (2025) · Russian Journal of Geriatric Medicine · doi:10.37586/2686-8636-4-2025-546-556

Additional file 1 of Lobeglitazone, a novel thiazolidinedione, for secondary prevention in patients with ischemic stroke: a nationwide nested case-control study

Yoo, J., Jeon, J., Baik, M., & Kim, J. (2024) · Figshare · doi:10.6084/m9.figshare.26587449

Antihyperglycemic Medications With Proven Cardiovascular Safety

Green, J. B. (2026) · Elsevier eBooks · doi:10.1016/b978-0-323-87862-3.00014-8

Primary cardiovascular preventive effect of thiazolidinedione in adults with type 2 diabetes: A nationwide cohort study in Korea

Choi, Y. S., Jeon, J., Baik, M., Yoo, J., & Kim, J. (2026) · Journal of Diabetes Investigation · doi:10.1111/jdi.70341

Structure of initial therapy for type 2 diabetes mellitus in 2025 in Moscow: Analysis of real-world clinical practice

Demidov, N. A. D., Demidova, T. Y., & Antsiferov, M. B. (2026) · FOCUS Endocrinology · doi:10.62751/2713-0177-2026-7-2-03

Oral Hypoglycemic Therapy in Metabolic Dysfunction-Associated Fatty Liver Disease

Karshina, O. O., Sabirov, I. S., & Mohammad, E. A. (2026) · Экспериментальная и клиническая гастроэнтерология · doi:10.31146/1682-8658-ecg-240-8-110-118

Targeting PPARγ beyond classical agonism: Context-dependent signaling, post-translational regulation, and precision therapeutic opportunities

Kuilya, M., Chowdhury, S., Chakraborty, P., & Kar, K. (2026) · Next research. · doi:10.1016/j.nexres.2026.102525

Pioglitazone for Primary and Secondary Prevention of Cardiovascular and Renal Outcomes in Patients with or at High Risk of Type 2 Diabetes: A Meta-Analysis

Khan, K. (2025) · International Journal of Medical and Biomedical Studies · doi:10.32553/ijmbs.v9i1.3091

Pioglitazone and the secondary prevention of cardiovascular disease. A meta-analysis of randomized-controlled trials

de Jong, M., van der Worp, H. B., van der Graaf, Y., Visseren, F. L. J., & Westerink, J. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0617-4 · Cited by 132 · see citing works

Pioglitazone and Risk of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: A Meta-analysis of Randomized Trials

Lincoff, A. M., Wolski, K., Nicholls, S. J., & Nissen, S. E. (2007) · JAMA · doi:10.1001/jama.298.10.1180 · Cited by 52 · see citing works

Favorable cardiovascular effects of pioglitazone: a meta-analysis

Uzunova, K. H., Filipova, E. P., Kalinov, K., & Vekov, T. Y. (2017) · Clinical Practice · doi:10.4172/clinical-practice.1000126

Rethinking the role of pioglitazone in modern diabetology as a cardiorenoprotective agent

Салухов, В. В., & Анатольевна, К. Е. (2022) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2022-16-10-10-21 · Cited by 10 · see citing works